5-MeO-DMT is the most powerful psychedelic there is. Mexican retreats use either Sonoran Desert toad secretion or synthetic — the safety and ethics differ.
5-MeO-DMT is not federally scheduled in Mexico. The General Health Law (Ley General de Salud), which lists controlled substances, does not include 5-MeO-DMT — neither the synthetic molecule nor toad-derived material. This is the legal posture that allows nearly every commercial 5-MeO-DMT retreat in the world to operate in Mexico, primarily near Tulum, Puerto Vallarta, the Riviera Maya, Tepoztlán, and in select Pacific-coast locations.
The Sonoran Desert toad itself is a different question. Incilius alvarius is listed under NOM-059-SEMARNAT-2010 as a species of special protection (Pr) under Mexican environmental law. Harvesting, transporting, or possessing live toads without authorization is restricted. The molecule extracted from the toad is not the regulated thing; the toad is. This is part of why responsible operators have moved toward synthetic sourcing.
For travelers, participating in a 5-MeO-DMT retreat in Mexico carries no Mexican legal risk. Bringing any form of 5-MeO-DMT back to the United States is a Schedule I federal offense — the substance is on the same schedule as heroin and LSD. The personal experience itself has no US legal implications; physical material crossing the border does.
The single most important question to ask any 5-MeO-DMT operator is: do you use synthetic 5-MeO-DMT, or toad-derived material? The two are not interchangeable, and the difference matters on three axes.
Synthetic 5-MeO-DMT is the single molecule 5-methoxy-N,N-dimethyltryptamine, manufactured under laboratory conditions, with purity verifiable by analytical chemistry. Toad-derived material is the dried parotoid-gland secretion of Incilius alvarius, which contains 5-MeO-DMT as the main psychoactive but also includes bufotenin (5-HO-DMT), several other tryptamines, and a class of cardiac steroids (bufadienolides) that are pharmacologically active and not fully characterized in low doses. The synthetic single-molecule preparation produces a more predictable dose-response and is what most clinical research uses.
Synthetic preparations are weighed and dosed with milligram precision. Toad secretion is dosed by appearance and operator judgment — alkaloid content varies between toads, between glands on the same toad, and across the year. This variability is a meaningful safety problem in a medicine where the difference between a workable and an overwhelming dose is small.
Producing synthetic 5-MeO-DMT does not require harvesting a wild animal. Producing toad-derived material does — and the harvesting itself causes stress, injury, and in some cases death to the toad even when the goal is non-lethal milking. See the conservation section below.
The leading responsible operators — including Tandava Retreats, the featured operator listed below — have moved entirely to synthetic. Indigenous Comcaac (Seri) voices, whose ancestral territory includes the toad's range, have publicly asked the ceremonial community to do the same. If an operator still uses toad-derived material, ask why; the answer is rarely defensible in 2026.
Incilius alvarius (formerly classified as Bufo alvarius) is endemic to the Sonoran Desert — northwestern Mexico (Sonora, parts of Sinaloa) and small areas of southern Arizona, southeastern California, and New Mexico. The species evolved in a narrow ecological niche, depends on summer monsoon rains to breed, and has always had a relatively small geographic range. Population pressures include habitat loss to agriculture and development, road mortality during breeding migrations, and — over the past decade and rising sharply since 2015 — over-collection for ceremonial 5-MeO-DMT extraction.
Field researchers including Robert Anthony Villa (Tumamoc Hill / University of Arizona) and conservation groups including the Tucson Herpetological Society have documented localized population declines in collection-pressured areas. The species is listed as a species of special protection (Pr) under Mexico's NOM-059-SEMARNAT-2010 and is under review by the IUCN. Indigenous voices from the Comcaac (Seri) community, whose ancestral territory overlaps the toad's range, have stated publicly that the toad is not a traditional ceremonial medicine in their culture and have asked the global psychedelic community to stop wild harvest.
The conservation case for switching to synthetic is essentially uncontested in 2026 among working ecologists. Operators that continue to use toad-derived material in spite of this consensus are doing so on aesthetic or marketing grounds, not on substantive ones.
5-MeO-DMT requires the strictest medical and psychiatric screening of any commonly used psychedelic. The intensity of the peak leaves no operational window to redirect a difficult experience, taper a dose, or pause; the screening is the safety floor.
A credible operator sends a detailed intake form, asks for current medications and supplements, and follows up by phone or video before accepting payment. Operators that decline 15–25% of applicants are screening properly. Operators that accept everyone are gambling with your stability.
A medically-supervised 5-MeO-DMT session is short in clock time but operationally intense. Typical structure at a credible retreat:
Most retreats run 1–3 sessions over a 3–5 day program, with at least 24–48 hours between dosings. More than three sessions in a week is not standard.
5-MeO-DMT consistently produces what survey research (Davis, Barsuglia, et al., 2018, Journal of Psychopharmacology) describes as "complete mystical experience" on standardized measures, at rates higher than any other studied psychedelic. Phenomenologically, the peak is closer to descriptions of nondual awareness in Advaita Vedanta, certain Buddhist contemplative texts, and Christian mystical literature than to the visual narrative content of ayahuasca, LSD, or psilocybin. Visuals are typically absent or minimal; what dominates is the dissolution of subject-object structure.
This phenomenology has two consequences. First, it is why participants frequently describe the experience as the most significant of their life. Second, it is why integration is non-negotiable: the rational mind has no framework for an experience that briefly suspended the self. Without active integration, the result can be a felt sense of having "seen something true" without the tools to live by it — and in vulnerable participants, destabilization, dissociation, or de-realization symptoms.
| Tier | 3–5 day program | What you get |
|---|---|---|
| Informal / unscreened | Under $1,500 | Often toad-derived, minimal screening, no medical infrastructure, one-shot session with no integration. Highest risk tier. |
| Entry medically-screened | $2,500–$3,500 | Synthetic 5-MeO, medical intake, one to two sessions, basic integration on-site, no follow-up therapy included. |
| Full program | $3,500–$5,500 | Synthetic 5-MeO, full screening, two to three sessions, two facilitators per participant, integration sessions before and after, written aftercare plan. |
| Premium / extended | $5,500–$8,500+ | Above plus extended pre- and post-retreat coaching (often 4–8 weeks), integration therapy referrals, smaller group sizes, sometimes paired with somatic or breathwork programs. |
Flights, ground transport, and travel insurance are extra. US insurance does not cover 5-MeO-DMT treatment (the substance is Schedule I in the US). Some operators offer payment plans; verify in writing before committing.
We do not operate, recommend, or take commissions from any retreat center. The operators below are ones we have written about because they publish medical-screening and safety protocols our editorial team can verify. Independent verification of credentials before you book is still on you.
Mexico
One of the few 5-MeO-DMT retreat operators with an explicit screening protocol; uses synthetic 5-MeO-DMT rather than toad-derived secretion, addressing both conservation concerns and purity.
Legal basis: Mexico — 5-MeO-DMT is not federally scheduled.
Note: Synthetic sourcing protects the Sonoran Desert toad (Incilius alvarius), which is threatened by over-harvesting for ceremonial use.
Integration after 5-MeO-DMT is not an add-on — it is the part of the treatment that determines whether the experience produces durable benefit or becomes a destabilizing memory. The pattern from clinicians who work with 5-MeO participants over time is consistent: the people who do well are the ones who put the experience into a framework (therapeutic, contemplative, or both) and then live by it over months. The people who struggle are the ones who treat the session as the work.
Good integration after 5-MeO looks like:
No. Ayahuasca contains DMT (N,N-DMT), a different molecule. 5-MeO-DMT (5-methoxy-N,N-DMT) is structurally similar but pharmacologically and phenomenologically distinct — higher 5-HT1A affinity, much more intense peak, non-visual, and dramatically shorter. Most experienced ayahuasca participants describe being unprepared for their first 5-MeO experience.
Bufotenin (5-HO-DMT) is also present in the Sonoran Desert toad secretion. It is structurally similar to 5-MeO but produces a less mystically-toned and more physically uncomfortable experience. Synthetic 5-MeO preparations contain only 5-MeO; toad-derived material contains both. This is one of the pharmacological arguments for synthetic over toad.
No — and any source that suggests otherwise is dangerous. The peak experience leaves you unable to monitor your own breathing or position. At minimum a 5-MeO session requires a sober, trained sitter present; at a credible retreat, two facilitators per participant is standard. Self-administration of 5-MeO has caused multiple documented deaths.
Effects compound psychologically — multiple sessions over a few days produce a different overall trajectory than a single session. Operators that run 2–3 sessions over a program often describe the second and third as opening doors the first did not. There is also evidence of acute tolerance: a second session within hours of the first produces a smaller effect.
Yes. GH Research is in clinical trials with a proprietary inhalable 5-MeO formulation (GH001) for treatment-resistant depression, with Phase 2 results suggesting rapid and substantial response. Beckley Psytech is conducting parallel research. Synthetic 5-MeO is the clinical-grade material in all of these programs.
Prior recreational experience does not waive a medical or psychiatric screening at a credible operator. The risks (serotonin syndrome, cardiovascular, psychiatric destabilization) are the same whether or not you have used the substance before.
Get retreat & safety updates
When operators, regulations, or safety guidance for 5-MeO-DMT (Bufo) Retreats in Mexico changes, we'll send you the update.
Suggest a tool, topic, or improvement that would make this site more useful.